Baxter International Inc. BAX announced today that it has agreed to
acquire the investigational hemophilia compound OBI-1 and related assets from
Inspiration BioPharmaceuticals, Inc. as well as certain other OBI-1 related
assets, including manufacturing operations, from Ipsen Pharma S.A.S. in
conjunction with Inspiration's ongoing bankruptcy proceedings. The transaction
is subject to bankruptcy court and regulatory approvals.
OBI-1 is a recombinant porcine factor VIII (rpFVIII) being investigated for
the treatment of bleeding in people with acquired hemophilia A and congenital
hemophilia A patients with inhibitors. Acquired hemophilia A is a rare,
potentially life-threatening bleeding disorder, which, unlike congenital
hemophilia, typically affects older adults and occurs equally in both males
and females.
''OBI-1 has the potential to address existing unmet needs of hemophilia
patients and is a strong strategic fit with Baxter's current hemophilia
portfolio,'' said Bruce Ewenstein, M.D., Ph.D., vice president of clinical
affairs in Baxter's BioScience business.
Under the terms of the agreement, Baxter will make an upfront payment of $50
million for the OBI-1 assets, including the manufacturing operations. In the
future, Baxter may make payments of up to $20 million in total based on
regulatory approval of the acquired hemophilia A indication in the United
States and first additional country. Additional amounts may be paid upon
approval of additional indications, through net sales payments, and as sales
milestones when sales exceed $100 million.
OBI-1 is currently in Phase III clinical studies in individuals with acquired
hemophilia A and those with congenital hemophilia A who have developed
inhibitors against human FVIII. OBI-1 received orphan drug designation in the
United States and Europe, and was recently granted fast track designation for
acquired hemophilia A by the United States Food and Drug Administration (FDA).
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in